Literature DB >> 18285601

Is response rate relevant to the phase II trial design of targeted agents?

Afshin Dowlati, Pingfu Fu.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18285601     DOI: 10.1200/JCO.2007.15.2827

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Trends in endpoint selection in clinical trials of advanced breast cancer.

Authors:  Seung Yeon Song; Heenam Seo; Gyungjin Kim; Ah Rong Kim; Eun Young Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-01       Impact factor: 4.553

2.  Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.

Authors:  Saurav Ghimire; Eunjung Kyung; Eunyoung Kim
Journal:  Lung       Date:  2013-05-30       Impact factor: 2.584

Review 3.  A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

Authors:  Michael J Grayling; Munyaradzi Dimairo; Adrian P Mander; Thomas F Jaki
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?

Authors:  Kerrie L McDonald; Grace Aw; Paul Kleihues
Journal:  Front Neurol       Date:  2013-01-18       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.